NexMR AG

NMR-based high throughput screening platform

NexMR aims to deliver fully characterized hits to support drug discovery pipelines.
Thanks to our proprietary technology using sensitivity-enhanced NMR we can screen libraries of thousands of molecules within days. We are also able to characterize the hits without idle time, as our technology encompasses affinity and structure determination.
Contrary to state-of-the-art methods (X-ray crystallography, surface plasmon resonance), we only require minimal assay development, allowing us to screen challenging targets which were not addressed so far.
The sample conditions used in NMR are milder and closer to physiological conditions than for other techniques, therefore facilitating the transition to further development.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

ETH Spin-off

http://www.vpf.ethz.ch/transfer/firmgruend/spinoff_list/by_years/2009

Website

NexMR AG

NMR-based high throughput screening platform

Headquarter:
Schlieren

Foundation Date:
May 2022

Technology:

  • Biotech

Sectors:

  • Biotech
  • Chemicals
  • Drug discovery
  • Services for companies
  • Screening
  • Small molecule drugs

Support received

  • Support venturekick